Ongoing in-depth research has raised new questions about treatment of NSCLC with EGFR mutations, the most important of which is the effect of combination therapy with EGFR-TKIs and other drugs, especially chemotherapy drugs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.